Real-world evidence strengthens case for oral antivirals in older COVID-19 patients
Amid ongoing hospitalisation, a leading GP calls for a focus on early testing and treatment
Tag: COVID-19 therapy
MBS telehealth existing relationship exemption for patients with COVID-19 gets the chop
Patients with COVID-19 will be restricted to telehealth consultations with their regular practice from 1 July after Medicare scraps their exemption to the existing relationship…
AstraZeneca makes ‘business decision’ to pull COVID-19 vaccine from Australia and EU
The TGA has withdrawn approval for COVID-19 vaccine Vaxzevria on the request of its sponsor, AstraZeneca. It finally closes a complex and controversial chapter in…
Paxlovid efficacy ‘not established’ for low-risk patients: study
Nirmatrelvir-ritonavir is no better than placebo for resolving symptoms in patients who are at low risk for severe COVID-19, results from an international study suggest.…
Helmet ventilation vs standard oxygen: Which is better for acute hypoxaemic respiratory failure?
Patients with acute hypoxaemic respiratory failure who receive oxygen via a helmet interface likely have better survival rates than those given standard oxygen therapy, a…
Molnupiravir lowers long COVID risk: study
Molnupiravir may cut the risk of long COVID symptoms as well as post-acute death, regardless of a patient’s vaccination status or prior infection, US epidemiologists…
COVID antivirals expert update: FAQ
An expert viewpoint on using the PBS-listed oral antivirals
COVID-19 antivirals: Doctors clash over PBS eligibility
Leading doctors have clashed over eligibility criteria for COVID-19 antivirals — specifically nirmatrelvir–ritonavir — following claims many patients were being “short-changed” and left unprotected. Federal…
COVID-19 antiviral still effective against Omicron, real-world studies show
Nirmatrelvir–ritonavir halves the risk of death and hospitalisation in patients with mild COVID-19 at risk of severe disease — even during the Omicron variant era…
Q&A: What does COVID-19 antiviral treatment look like in 2023?
Co-chair of the COVID-19 clinical evidence taskforce discusses emerging treatments and the taskforce’s uncertain future
